CompanyLNTHNasdaqBedford, MA

Lantheus Holdings, Inc.

Lantheus develops radiopharmaceuticals for diagnostic imaging and therapeutic applications.

SEC EDGAR ClinicalTrials.gov lantheus.com

20-FSep 30Latest SEC filing

Aug 13Latest story

August 2026

FDA approves TAUKLARIFY, new molecular entity from Cerveau Lantheus

Aug 13Regulatory decisionflorquinitau f-18 Lantheus Holdings, Inc.

Lantheus posts Q2 2026 results, pulls guidance amid pending Curium merger

Aug 6Quarterly updateLantheus Holdings, Inc.

Lantheus merger with Curium subsidiary confirmed at up to $114.50 per share

Aug 3PartnershipLantheus Holdings, Inc.